Protective role of ginsenoside Rg1 in the dynamic progression of liver injury to fibrosis: a preclinical meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Ginsenoside Rg1 effectively mitigates liver injury and fibrosis by reducing inflammation, oxidative stress, and apoptosis. This systematic review supports its therapeutic potential for liver disease progression.
Area Of Science
- Hepatology
- Pharmacology
- Natural Products
Background
- Liver injury progression to fibrosis lacks effective treatments.
- Ginsenoside Rg1 shows hepatoprotective properties, but preclinical evidence is limited.
- Systematic review needed to evaluate therapeutic potential for liver injury and fibrosis.
Purpose Of The Study
- Evaluate efficacy of ginsenoside Rg1 in animal models of liver injury and fibrosis.
- Investigate underlying mechanisms of ginsenoside Rg1 action.
- Provide basis for future clinical investigation of ginsenoside Rg1.
Main Methods
- Systematic review of preclinical studies (PubMed, Web of Science, Embase).
- Quality assessment using SYRCLE's risk of bias tool.
- Meta-analysis and dose-response analysis to determine effective dose range.
Main Results
- Ginsenoside Rg1 improved liver function markers (ALT, AST) and reduced fibrosis indicators (α-SMA, HYP, PCIII).
- Beneficial effects observed on inflammation, oxidative stress, and apoptosis markers.
- Effective dose range identified as 4-800 mg/kg/d.
Conclusions
- Ginsenoside Rg1 (4-800 mg/kg/d) mitigates liver injury and fibrosis progression.
- Mechanisms include anti-inflammatory, antioxidative, and anti-apoptotic pathways.
- Supports ginsenoside Rg1 as a potential therapeutic agent for liver disease.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
